Valuation: argenx SE

Market Cap 55.18B 47.73B 44.57B 40.89B 76.9B 5,251B 78.13B 523B 205B 2,632B 207B 203B 8,702B P/E 2026 *
31.4x
P/E 2027 * 25.3x
Enterprise Value 49.76B 43.04B 40.2B 36.87B 69.36B 4,736B 70.46B 472B 185B 2,374B 187B 183B 7,847B EV / Sales 2026 *
8.03x
EV / Sales 2027 * 6.22x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day+1.25%
1 week+2.44%
Current month+2.44%
1 month-6.03%
3 months+13.71%
6 months+9.72%
Current year+6.47%
1 week 717.4
Extreme 717.4
777.4
1 month 717.4
Extreme 717.4
829.2
Current year 568.4
Extreme 568.4
833.6
1 year 544.2
Extreme 544.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.5
Extreme 12.5
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
11/23/25 Fiscal year

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+1.25%+2.44%+32.55%+72.63% 55.18B
+8.49%+20.55%+69.74%+109.30% 68.12B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
+2.12%+3.54%+445.77%+184.49% 12.38B
Average +3.67%+10.87%+92.19%+204.74% 27.59B
Weighted average by Cap. +4.26%+12.67%+67.26%+169.21%

Financials

2026 *2027 *
Net sales 6.2B 5.36B 5.01B 4.59B 8.64B 590B 8.78B 58.74B 23.05B 296B 23.27B 22.76B 977B 7.61B 6.58B 6.15B 5.64B 10.61B 724B 10.78B 72.13B 28.31B 363B 28.58B 27.95B 1,200B
Net income 1.86B 1.61B 1.51B 1.38B 2.6B 177B 2.64B 17.66B 6.93B 88.91B 7B 6.85B 294B 2.47B 2.14B 2B 1.83B 3.45B 235B 3.5B 23.45B 9.2B 118B 9.29B 9.09B 390B
Net Debt -5.42B -4.69B -4.38B -4.01B -7.55B -516B -7.67B -51.34B -20.15B -258B -20.34B -19.9B -854B -7.83B -6.77B -6.32B -5.8B -10.91B -745B -11.08B -74.17B -29.11B -373B -29.39B -28.74B -1,234B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-07 €763.20 +1.25% 48,751
26-08-06 €753.80 +0.69% 83,469
26-08-05 €748.60 +2.83% 101,341
26-08-04 €728.00 +0.80% 89,773
26-08-03 €722.20 -3.06% 94,348
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
882.31USD
Average target price
1,037.68USD
Spread / Average Target
+17.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock